多西紫杉醇联合顺铂治疗晚期乳腺癌肺转移的临床观察  

Clinical Observation of Combination of Docetaxel and Cisplatin on the Treatment of Breast Cancer Lung Metastasis

作　　者：关春文[1] 田梅玲[1] 李俊伟[1] 

机构地区：[1]濮阳市人民医院放疗科,河南濮阳457000

出　　处：《河南职工医学院学报》2008年第2期126-128,共3页Journal of Henan Medical College For Staff and Workers

摘　　要：目的探讨多西紫杉醇联合顺铂治疗乳腺癌肺转移的临床疗效和毒副作用。方法自2004年8月-2006年8月，对临床确诊的28例乳腺癌肺转移患者给予周剂量多西紫杉醇25-40mg／m2，第1、8、15d给药；顺铂20mg／m2静脉滴注，第2—4d。每28d为一周期，完成2周期化疗后评价疗效，有效病例4周后确认。结果28例患者均可评价疗效。按WHO标准评价疗效及毒性，完全缓（CR）3例、部分缓（PR）13例，无变化（SD）11例，病进（PD）1例，总有效率（CR＋PR）为57．1％（16／28）。主要不良反应为骨髓抑制及胃肠道反应。结论周剂量多西紫杉醇联合顺铂是治疗乳腺癌肺转移的有效化疗方案，不良反应患者能耐受。Objective To explore the clinical and toxic effects of combinatin of docetaxed and cisplation on the treatment of breast cancer lung metastasis. Methods 28 cases of breast cancer lung metastasis diagnosed from Aug. 2004 to Aug. 2006 were treated with docetaxel and cisplatin. The dose of docetaxel was 25 -40 mg/m2 and it was medicated on day 1,8 and 15. The cisplatin （20 mg/m2） was in jected through intravenous on day 2,3 and 4. The chemotherapy was repeated every 28 days on two cycles. Results The clinical and toxic effects were evaluated according to the standards of WHO. The number of CR, PR,SD and PD were 3,13,11 and 1 respectively. The effective rate （CP ＋ PR） was 57.1% （16/28）. The main side effects were bone marrow inhibition and enterograstric reaction. Conclusion Combination of docetaxel and cisplatin on the treatment of breast cancer lung metastasis was an effective method.

关 键 词：乳腺肿瘤 多西紫杉醇 肿瘤/药物疗法 联合 

分 类 号：R737.9[医药卫生—肿瘤]